Basket | Login | Register


WP6: Characterisation of transgenics and development of imaging, electrophysiological, and biological markers for disease-modifying drugs (Pre-clinical studies)

Work Packages

Pharmacog Logo

Main Objectives

  • To identify a translational biomarker matrix of imaging, electrophysiological, and biological markers that correlate with central amyloid pathophysiology in PD - APP and APP / PS-1 models
  • To identify a translational biomarker matrix that is sensitive to amyloid lowering agents and thereby facilitates pre-clinical PK / PD studies and identify potential pharmacodynamic markers for use in early clinical studies.
  • To characterize novel models of neurodegeneration (i.e. Tau transgenic mice and/or lemurs) to investigate their potential utility as pharmacodynamic models for disease modifying agents with neuroprotective properties.
  • To develop animal models with marker-based signatures of AD progression homologous to those shown and validated in the clinic (WP5)

WP Leads

Industry lead: Dr Sophie Dixl (Lilly)
SME lead : Dr Phil Verwaerde (Alzprotect)

WP Partners

  • University of Murcia, Spain
  • CNRS, France
  • University of Verona, Italy
  • IRCCS-FBF, Italy
  • University of Foggia, Italy
  • Mario Negri Institute, Italy
  • GSK
  • Lilly
  • Janssen
  • Roche
  • Lundbeck
  • AstraZeneca
  • Servier
  • Merck
  • ICDD
  • AlzProtect
  • Exonhit
  • Innovative Health Diagnostic
  • Eisai Ltd



Last Updated: Tuesday 26 April 2011


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations